Overall survival and progression-free survival by PD-L1 status among endometrial cancer patients treated with pembrolizumab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel plus placebo in the NRG GY018 trial

被引：1

作者：

Eskander, Ramez ^{[1
]}

Sill, Michael ^{[2
]}

Beffa, Lindsey ^{[3
]}

Moore, Richard ^{[4
]}

Hope, Joanie ^{[5
]}

Musa, Fernanda ^{[5
]}

Mannel, Robert ^{[6
]}

Shahin, Mark ^{[7
]}

Cantuaria, Guilherme ^{[8
]}

Girda, Eugenia ^{[9
]}

Mathews, Cara ^{[10
]}

Kavecansky, Juraj ^{[11
]}

Leath, Charles ^{[12
]}

Gien, Lilian ^{[13
]}

Hinchcliff, Emily ^{[14
]}

Lele, Shashikant ^{[2
]}

Landrum, Lisa ^{[15
]}

Backes, Floor ^{[16
]}

O'Cearbhaill, Roisin ^{[17
]}

Liu, Rebecca ^{[18
]}

Hill, Emily ^{[19
]}

Thaker, Premal H. ^{[20
]}

John, Veena ^{[21
]}

Powell, Matthew ^{[20
]}

Aghajanian, Carol

机构：

[1] Univ Calif San Diego, La Jolla, CA 92093 USA

[2] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[3] Cleveland Clin, Cleveland, OH 44106 USA

[4] Univ Rochester, Med Ctr, Rochester, NY 14642 USA

[5] Pacific Canc Res Consortium NCORP, Seattle, WA USA

[6] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA

[7] Thomas Jefferson Univ, Willow Grove, PA USA

[8] Georgia NCI Community Oncol Res, Atlanta, GA USA

[9] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[10] Women & Infants Hosp Rhode Isl, Providence, RI USA

[11] Kaiser Permanente, Walnut Creek, CA USA

[12] Univ Alabama Birmingham, Birmingham, AL USA

[13] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada

[14] Northwestern Univ, Chicago, IL 60611 USA

[15] Indiana Univ, Indianapolis, IN 46204 USA

[16] Ohio State Univ, Columbus, OH 43210 USA

[17] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[18] Trinity Hlth IHA Med Grp, Michigan Canc Res Consortium NCORP, Ypsilanti, MI USA

[19] Univ Iowa, Iowa City, IA USA

[20] Washington Univ St Louis, St Louis, MO USA

[21] Northwell Hlth Canc Inst, Lake Success, NY USA

来源：

GYNECOLOGIC ONCOLOGY | 2024年 / 190卷

关键词：

D O I：

10.1016/j.ygyno.2024.07.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

02 [LBA]

引用

页码：S5 / S5

页数：1

共 38 条

[1] Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/ paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial
Eskander, R. N.
Sill, M.
Miller, A.
Beffa, L.
Moore, R.
Hope, J.
Musa, F.
Mannel, R.
Shahin, M. S.
Canturia, G.
Girda, E.
Mathews, C.
Kavecansky, J.
Leath, C. A., III
Gien, L.
Hinchcliff, E.
Lele, S.
Powell, M. A.
Aghajanian, C.
ANNALS OF ONCOLOGY, 2023, 34 : S1284 - S1284
[2] Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
Eskander, Ramez N.
Sill, Michael W.
Beffa, Lindsey
Moore, Richard G.
Hope, Joanie M.
Musa, Fernanda B.
Mannel, Robert S.
Shahin, Mark S.
Cantuaria, Guilherme H.
Girda, Eugenia
Lokich, Elizabeth
Kavecansky, Juraj
Leath, Charles A.
Gien, Lilian T.
Hinchcliff, Emily M.
Lele, Shashikant B.
Landrum, Lisa M.
Backes, Floor
O'Cearbhaill, Roisin E.
Baghdadi, Tareq Al
Hill, Emily K.
Thaker, Premal H.
John, Veena S.
Welch, Stephen
Fader, Amanda N.
Powell, Matthew A.
Aghajanian, Carol
NATURE MEDICINE, 2025,
[3] Prediction of Progression-Free Survival and Response to Paclitaxel Plus Carboplatin in Patients With Recurrent or Advanced Cervical Cancer
Hisamatsu, Takeshi
Mabuchi, Seiji
Yoshino, Kiyoshi
Fujita, Masami
Enomoto, Takayuki
Hamasaki, Toshimitsu
Kimura, Tadashi
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2012, 22 (04) : 623 - 629
[4] ABCB1 Variation Affects Myelosuppression, Progression-free Survival and Overall Survival in Paclitaxel/Carboplatin-treated Ovarian Cancer Patients
Bjorn, Niclas
Falk, Ingrid Jakobsen
Vergote, Ignace
Green, Henrik
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 (03) : 277 - 287
[5] IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab plus carboplatin plus paclitaxel or nab-paclitaxel vs carboplatin plus nab-paclitaxel in 1L advanced squamous NSCLC
Socinski, M. A.
Rittmeyer, A.
Shapovalov, D.
Orlandi, F.
McCleod, M.
Soo, R. A.
Palmero, R.
Kozuki, T.
Migliorino, M. R.
Koynov, K. D.
Berard, H.
Hughes, B. G. M.
Yu, W.
Graupner, V.
Sun, S. W.
Kowanetz, M.
Hoang, T.
Lin, W.
Jotte, R. M.
ANNALS OF ONCOLOGY, 2018, 29
[6] Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel- paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial
Powell, M. A.
Bjorge, L.
Willmott, L.
Novak, Z.
Black, D.
Gilbert, L.
Sharma, S.
Valabrega, G.
Landrum, L. M.
Gropp-Meier, M.
Stuckey, A.
Boere, I.
Gold, M. A.
Segev, Y.
Gill, S. E.
Gennigens, C.
Sebastianelli, A.
Shahin, M. S.
Pothuri, B.
Monk, B. J.
Buscema, J.
Coleman, R. L.
Slomovitz, B. M.
Ring, K. L.
Herzog, T. J.
Balas, M. M.
Grimshaw, M.
Stevens, S.
Lai, D. W.
Mccourt, C.
Mirza, M. R.
ANNALS OF ONCOLOGY, 2024, 35 (08) : 728 - 738
[7] Pembrolizumab versus placebo in addition to carboplatin and paclitaxel for measurable stage 3 or 4a, stage 4b or recurrent endometrial cancer: The phase 3, NRG GY018 study
Eskander, Ramez
Sill, Michael
Beffa, Lindsey
Moore, Richard
Hope, Joanie
Musa, Fernanda
Mannel, Robert
Shahin, Mark
Cantuaria, Guilherme
Girda, Eugenia
Mathews, Cara
Kavecansky, Juraj
Leath, Charles
Gien, Lilian
Hinchcliff, Emily
Lele, Shashikant
Lele, Shashikant
Landrum, Lisa
Backes, Floor
O'Cearbhaill, Roisin
Liu, Rebecca
Hill, Emily
Thaker, Premal
John, Veena
Powell, Matthew
Aghajanian, Carol
GYNECOLOGIC ONCOLOGY, 2023, 176 : S42 - S43
[8] PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials
de Moraes, Francisco Cezar Aquino
Pasqualotto, Eric
Lopes, Lucca Moreira
Souza, Maria Eduarda Cavalcanti
Rodrigues, Anna Luiza Soares de Oliveira
de Almeida, Artur Menegaz
Stecca, Carlos
Fernandes, Marianne Rodrigues
dos Santos, Ney Pereira Carneiro
BMC CANCER, 2023, 23 (01)
[9] PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials
Francisco Cezar Aquino de Moraes
Eric Pasqualotto
Lucca Moreira Lopes
Maria Eduarda Cavalcanti Souza
Anna Luíza Soares de Oliveira Rodrigues
Artur Menegaz de Almeida
Carlos Stecca
Marianne Rodrigues Fernandes
Ney Pereira Carneiro dos Santos
BMC Cancer, 23
[10] Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis
Masashi Takano
Toru Sugiyama
Nobuo Yaegashi
Mitsuaki Suzuki
Hiroshi Tsuda
Satoru Sagae
Yasuhiro Udagawa
Kazuo Kuzuya
Junzo Kigawa
Satoshi Takeuchi
Hitoshi Tsuda
Takuya Moriya
Yoshihiro Kikuchi
International Journal of Clinical Oncology, 2007, 12 : 256 - 260

← 1 2 3 4 →